Benefits
Healthy energy and reduced tiredness
A small, industry-funded (Horphag Research) pilot registry study in adults reporting unexplained fatigue found Robuvit® 300 mg/day was associated with modest improvements in self-reported energy, tiredness, sleep, and daytime functioning versus a control group. It was not a blinded RCT; the effects are proposed to relate to support of mitochondrial function and antioxidant activity.
Athletic endurance and performance
Robuvit® supplementation (300 mg/day for 4 weeks) significantly improved performance in long-distance triathletes and runners, reducing post-race fatigue, improving recovery, and increasing time-to-exhaustion in subsequent testing. The urolithin-mediated mitophagy and mitochondrial biogenesis mechanisms are proposed to contribute to these effects, which come from a single small, industry-funded study.
Antioxidant and mitophagy activation
Like pomegranate-derived urolithins, oak-derived urolithins activate mitophagy — the selective autophagy of damaged mitochondria that maintains mitochondrial quality. This cellular housekeeping mechanism improves the overall health of the mitochondrial pool, enhancing energy production efficiency and reducing the accumulation of dysfunctional mitochondria associated with aging.
Mechanism of action
Urolithin production via robur ellagitannin metabolism
Gut bacteria convert robur ellagitannins (roburins, vescalagine) to urolithins through sequential demethylation and lactonization reactions. Urolithin A — the primary bioactive metabolite — activates mitophagy via PINK1/Parkin pathway and induces mitochondrial biogenesis via PGC-1α, improving mitochondrial quality and energy production capacity.
Mitochondrial biogenesis via PGC-1α
Robuvit® and its urolithin metabolites are thought to activate PGC-1α — a regulator of mitochondrial biogenesis — in preclinical models. Greater mitochondrial capacity is proposed to support ATP production and aerobic energy metabolism; organ-specific effects in humans are not established.
NF-κB and oxidative stress reduction in liver and muscle
Oak ellagitannins and their metabolites inhibit NF-κB activation in liver and muscle tissue, reducing inflammatory cytokine production and protecting cells from exercise-induced and toxic oxidative damage. This anti-inflammatory activity underlies both the liver-protective and exercise-recovery benefits of Robuvit®.
Clinical trials
Supplement pilot registry study of Robuvit® (300 mg/day French oak wood extract) vs a control group in adults with unexplained chronic fatigue. This was a registry/pilot study, not a blinded randomized controlled trial. (Belcaro et al. 2015)
70 adults with chronic fatigue.
Robuvit® reduced fatigue scores (Multidimensional Fatigue Inventory), improved energy levels, enhanced sleep quality vs placebo. Industry-funded (Horphag Research, makers of Pycnogenol®). Effect sizes modest.
Small single-manufacturer (Horphag-funded) study of Robuvit® (300 mg/day) in long-distance triathlon competitors, from the same Belcaro/Chieti research group; a performance study rather than a blinded outcome RCT. (Vinciguerra et al. 2015)
Long-distance triathletes.
Robuvit® reduced post-race fatigue scores, improved recovery metrics, enhanced time-to-exhaustion. Industry-funded.